Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice
- PMID: 1647416
- PMCID: PMC296025
- DOI: 10.1172/JCI115283
Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice
Abstract
Expression of the human IL-6 gene in EBV-immortalized normal human B lymphocytes following retroviral-mediated transduction rendered these cells highly tumorigenic in athymic mice. The tumors were lymphomas composed of the originally inoculated human lymphoblastoid cells. Co-injection of IL-6 expressing EBV-immortalized cells with IL-6 nonexpressing control cells resulted in increased tumorigenicity of the IL-6 nonexpressing cells. The lymphoblastoid cells expressing IL-6 were indistinguishable from parental cell lines in morphology and in a variety of cell surface characteristics, and did not exhibit growth advantage over parental cell lines in vitro, such that increased tumorigenicity is unlikely to depend upon a direct oncogenic effect of IL-6 on the B cells. Rather, at high concentrations, IL-6 markedly inhibits human lymphoblastoid cell killing by IL-2-activated murine splenocytes in vitro, suggesting that IL-6-related tumorigenicity might depend upon IL-6 inhibiting cytotoxicity at the tumor site. Thus, production of IL-6 by tumor cells that results in natural killer cell dysfunctions illustrates a novel mechanism of tumor cell escape from immune surveillance.
Similar articles
-
Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model.Cell Mol Biol (Noisy-le-grand). 1996 Jul;42(5):769-78. Cell Mol Biol (Noisy-le-grand). 1996. PMID: 8832108
-
Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.Cancer Res. 1998 Nov 1;58(21):4930-9. Cancer Res. 1998. PMID: 9810002
-
In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.Cancer Gene Ther. 1997 Nov-Dec;4(6):366-76. Cancer Gene Ther. 1997. PMID: 9408607
-
High level expression of the homeobox gene HB24 in a human T-cell line confers the ability to form tumors in nude mice.Cancer Res. 1993 Jan 15;53(2):373-7. Cancer Res. 1993. PMID: 8093351
-
The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role.J Immunol. 1999 Jun 1;162(11):6650-7. J Immunol. 1999. PMID: 10352282
Cited by
-
Inflammation in cystic fibrosis.Mediators Inflamm. 1996;5(2):121-43. doi: 10.1155/S096293519600021X. Mediators Inflamm. 1996. PMID: 18475710 Free PMC article. No abstract available.
-
Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.Br J Cancer. 1999 May;80(3-4):407-11. doi: 10.1038/sj.bjc.6690371. Br J Cancer. 1999. PMID: 10408846 Free PMC article. Clinical Trial.
-
Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.J Virol. 2005 Nov;79(22):13984-92. doi: 10.1128/JVI.79.22.13984-13992.2005. J Virol. 2005. PMID: 16254334 Free PMC article.
-
Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.Trans Am Clin Climatol Assoc. 2006;117:55-73; discussion 73-4. Trans Am Clin Climatol Assoc. 2006. PMID: 18528464 Free PMC article. Review.
-
Potential contribution of naïve immune effectors to oral tumor resistance: role in synergistic induction of VEGF, IL-6, and IL-8 secretion.Cancer Immunol Immunother. 2008 Mar;57(3):359-66. doi: 10.1007/s00262-007-0375-3. Epub 2007 Aug 17. Cancer Immunol Immunother. 2008. PMID: 17703300 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical